HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • How Will Generic Drugs Affect HIV Treatment in the U.S.?

    In the U.S., in that many of the antiretroviral drugs that are commonly used today are approaching their patent expirations. So we can begin to conceptualize the use of generics in the U.S. and the potential cost savings. An Interview With Treatment Action Group's Tim Horn.

    14 hours ago | The Body
  • Michel Sidibé: Thailand leads way to ending Aids

    This month, through its innovative Ending Aids by 2030 strategy, Thailand became the first country in Asia to offer HIV treatment to every person living with HIV.

    28 October 2014 | Bangkok Post
  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
  • Why I Refused, Then Later Embraced, HIV Treatment

    "On good days, adhering to my pill is a positive affirmation of my life, an exercise in self-love. On bad days, it's just a pill I need to swallow, not terribly bitter but as mildly annoying as having to shave or tie my shoelaces every day. It's yet another thing to add to my list of things, but I do it anyway." Josh Kruger on his ambiguous relationship to HIV treatment.

    01 October 2014 | TheBody.com
  • PREZCOBIX™ now available for Canadians living with HIV

    Janssen Inc. announced today that PREZCOBIX™ (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. The new treatment option combining a protease inhibitor with a boosting agent reduces the number of pills required to manage HIV.

    18 September 2014 | Newswire.ca
  • CDC Launches HIV Treatment Awareness Campaign

    “HIV Treatment Works” is a new awareness campaign from the U.S. Centers for Disease Control and Prevention (CDC).

    17 September 2014 | Poz
  • Long acting HIV drugs to be developed

    HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of ‘pill fatigue’.

    15 September 2014 | University of Liverpool press release
  • Uganda: Aids Patients Reject Bitter ARVs

    The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).

    10 September 2014 | Allafrica.com
  • New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

    An experimental single-tablet regimen containing a new version of tenofovir (tenofovir alafenamide or TAF) and the HIV protease inhibitor darunavir (Prezista) worked as well as a similar regimen containing the older tenofovir disoproxil fumarate (TDF) formulation,but it had less detrimental effects on kidney function and bone density, as study presented at the recent ICAAC conference heard.

    09 September 2014 | HIVandhepatitis.com
  • EU marketing authorization for ViiV Healthcare HIV drug Triumeq

    The European Commission has granted marketing authorization for ViiV Healthcare’s Triumeq(dolutegravir 50mg/abacavir 600mg/lamivudine 300mg) tablets for the treatment of HIV in adults and adolescents aged 12 years and older.

    04 September 2014 | Pharma Letter
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.